Leading Radiology Forward
.
2021 Guidance
For 2021, we believe our business will continue to strengthen as COVID-19 restrictions are further lifted
across the country and in our markets
2H 2020 Revenue and Adj. EBITDA of $600 million and $96 million, respectively
о
Run rate greater than our conservative guidance recently released for 2021
Operating Metric
2021 Guidance Range
Total Net Revenue
$1,250 million - $1,300 million
Adjusted EBITDA
$180 million - $190 million
Capital Expenditures (1)
$70 million $75 million
Cash Paid for Interest
Free Cash Flow Generation (2)
$39 million - $44 million
$60 million - $70 million
* End of year 2021 targeted leverage below 3.25x
*
1. Net of proceeds from the sale of equipment, imaging centers and joint venture interests, and excludes New Jersey Imaging Network capital expenditures.
2. Defined as Adjusted EBITDA less Capital Expenditures and Cash Paid for Interest.
RadNet.
Leading Radiology Forward
7View entire presentation